Xie Y, Ge R, Sang D, et al. - This multicenter, retrospective study was conducted by researchers to establish not only the safety and effectiveness of lapatinib plus capecitabine (LX) and lapatinib plus trastuzumab [HL] plus one chemo regimen (HLC) among patients previously treated with trastuzumab and taxane but also the treatment trend following the progression of lapatinib in clinical practice. They assessed the medical records retrospectively of all metastatic breast cancer (MBC) patients with human epidermal growth factor receptor-2 (HER2) positive disease who progressed on prior trastuzumab-containing regimens (advanced setting) and a taxane (any setting) and received lapatinib-based treatment from 2015 to 2018 in five institutions in China. In total, 242 patients were available for analysis. Continuation of lapatinib exhibited superior mPFS results vs the non-anti-HER2 treatment and similar outcomes compared with a switch to other anti-HER2 treatments. HLC offered a new dual-targeting treatment alternative for the later lines therapy of patients with HER2 positive MBC in patients who had progressed on prior trastuzumab-base therapy. Furthermore, evidence was provided on the cross-line use of lapatinib.